I am a stock analyst with over 20 years of experience in quantitative research, financial modeling, and risk management. My focus is on equity valuation, market trends, and portfolio optimization to uncover high-growth investment opportunities. As a former Vice President at Barclays, I led teams in model validation, stress testing, and regulatory finance, developing a deep expertise in both fundamental and technical analysis. Alongside my research partner (also my wife), I co-author investment research, com ...

With a market capitalization of $195.79 billion, Merck & Co. (NYSE: MRK ) is not only one of the largest pharmaceutical companies on the planet, it's one of the largest companies on the planet period. Over the years, the company has seen mixedCrude Value Insights offers you an investing service and community focused on oil and natural gas. We focus on cash flow and the companies that generate it, leading to value and growth prospects with real potential.Subscribers get to use a 50+ stock model account, in-d ...

Merck (MRK) and Japan’s Daiichi Sankyo announced the dosing of the first patient in the phase III IDeate-Esophageal01 study evaluating their B7-H3 directed DXd antibody-drug conjugate (ADC), ifinatamab deruxtecan (I-DXd), in certain patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC).The IDeate-Esophageal01 study will evaluate the safety and efficacy of I-DXd versus an investigator’s choice of chemotherapy in ESCC patients whose disease progressed following treatment with a platin ...

Merck & Co., Inc. (NYSE:MRK) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ET Company Participants Jannie Oosthuizen - President Peter Dannenbaum - Senior Vice President, Investor Relations Marjorie Green - SVP, Head of Oncology Clinical Development Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this, meeting. I'm Tim Anderson, the U.S. large-cap pharma and biotech analyst at Bank of America. We have the pleasure of speaking with Merck to ...

Merck & Co (MRK) 2025 Conference May 14, 2025 01:40 PM ET Speaker0 Off our next session. Thanks for joining us for this meeting. I'm Tim Anderson, the US Large Cat Pharma and Biotech Analyst at Bank of America. We have the pleasure of speaking with Merck today. Three folks on stage, Jani Oyslisen, did I get it right? Who's President US Human Health. He's held this role since 2022. He joined Merck in 2014, serving in various roles internationally as well. Most recently led global marketing for oncology. And ...

Washington, D.C. 20549 UNITED STATES FORM 10-Q SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Rahway New Jersey 07065 (Address of principal executive offices) (zip code) (Registrant's telephone number, including area code) (732) 594-4000 For the transition period from ______ to ______ Commissi ...

Parkev Tatevosian, CFA has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool. ...

Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs.The new facility will produce biologic drugs and Keytruda, becoming Merck’s first in-house US site to make the blockbuster cancer treatment, the company said.Merck said last week its biggest tariff exposure is through Keytruda and it has enough US inventory for this year. It estimated $200 million in additional costs for the levies implemented to ...

Merck (MRK) reported its first-quarter 2025 results last week, beating estimates for both earnings and sales. Adjusted earnings of $2.22 per share rose 12% year over year, excluding foreign exchange impact. Revenues of $15.53 billion rose 1% year over year as higher sales of blockbuster cancer drug, Keytruda, new products like Welireg, Winrevair and Capvaxive and strong performance of the Animal Health segment were partially offset by lower sales of the HPV vaccine Gardasil in China. Keytruda, the biggest p ...

iREIT+HOYA Capital is the premier income-focused investing service on Seeking Alpha. Our focus is on income-producing asset classes that offer the opportunity for sustainable portfolio income , diversification , and inflation hedging . Get started with a Free Two-Week Trial and take a look at our top ideas across our exclusive income-focused portfolios.There is no denying that a tumultuous April has created a number of dividend bargains. This enables investors to cherry-pick the highest quality names that h ...